Keros Therapeutics operates in the competitive biopharmaceutical and clinical-stage biotechnology landscape, focusing primarily on developing novel therapeutics targeting the transforming growth factor-beta protein superfamily. Its primary competitors include various clinical-stage and commercial-stage biotechnology firms engaged in developing treatments for rare hematologic, oncologic, and endocrine disorders. Comparable peer companies often evaluated alongside Keros by market analysts include firms such as Acceleron Pharma prior to its acquisition, specialized rare disease players like Regulus Therapeutics, Capricor Therapeutics, and other emerging gene therapy and protein-engineering companies striving to address similar high-unmet-need conditions through innovative molecular pathways.